

need thereof with no or minimal adverse side effects. Accordingly, in one aspect, the present invention refers to the use of an anti-CGRP receptor antibody or antigen-binding fragment thereof for preparation of a medicament for preventing or reducing the occurrence of migraine headache in a patient in need thereof, wherein the medicament is formulated for administration at a monthly dose of 35 mg to 210 mg, wherein the anti-CGRP receptor antibody or antigen-binding fragment thereof comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65. In another aspect, the present invention refers to the use of an anti-CGRP receptor antibody or antigen-binding fragment thereof for preparation of a medicament for prophylactically treating a patient for migraine headache, wherein the medicament is formulated for administration at a monthly dose of 35 mg to 210 mg, wherein the anti-CGRP receptor antibody or antigen-binding fragment thereof comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65. Also disclosed herein is a method for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor antibody or antigen-binding fragment thereof at a dose of about 35 mg to about 210 mg per month. In some examples, the present disclosure provides a method for prophylactically treating a patient for migraine comprising administering to the patient an anti-CGRP receptor antibody or antigen-binding fragment thereof at a dose of about 35 mg to about 210 mg per month.

[0010] In some examples of the methods, the anti-CGRP receptor antibody or binding fragment thereof is administered to the patient at a dose sufficient to reduce the number of monthly migraine headache days experienced by the patient as compared to the number of monthly migraine headache days prior to treatment or the number of monthly migraine headache days experienced by a patient not receiving the anti-CGRP receptor antibody or binding fragment thereof. In some examples, the dose of anti-CGRP receptor antibody or binding fragment thereof administered to the patient is sufficient to reduce the number of

CLAIMS

What is claimed:

1. Use of an anti-CGRP receptor antibody or antigen-binding fragment thereof for preparation of a medicament for preventing or reducing the occurrence of migraine headache in a patient in need thereof, wherein the medicament is formulated for administration at a monthly dose of 35 mg to 210 mg, wherein the anti-CGRP receptor antibody or antigen-binding fragment thereof comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65.
2. Use of an anti-CGRP receptor antibody or antigen-binding fragment thereof for preparation of a medicament for prophylactically treating a patient for migraine headache, wherein the medicament is formulated for administration at a monthly dose of 35 mg to 210 mg, wherein the anti-CGRP receptor antibody or antigen-binding fragment thereof comprises a CDRH1 having the sequence of SEQ ID NO:14, a CDRH2 having the sequence of SEQ ID NO:23, a CDRH3 having the sequence of SEQ ID NO:34, a CDRL1 having the sequence of SEQ ID NO:44, a CDRL2 having the sequence of SEQ ID NO:55, and a CDRL3 having the sequence of SEQ ID NO:65.
3. The use of claim 1 or 2, wherein the monthly dose is 70 mg to 140 mg.
4. The use of claim 1 or 2, wherein the monthly dose is about 70 mg.
5. The use of claim 1 or 2, wherein the monthly dose is about 140 mg.
6. The use of any one of claims 1 to 5, wherein the medicament is formulated for administration parenterally.
7. The use of claim 6, wherein the parenteral administration is subcutaneous administration.